Concentration in the market liquidity of Indian equities
by Hasita Pattipaty, Atibhi Sharma, Susan Thomas.
Indian equity markets are some of the most active in the world today. According to the World Federation of Exchanges, order-book trades at the National Stock Exchange (NSE) grew from 1.6 billion in 2010 to 8.2 billion in 2025 (NYSE grew from 2.1 billion to 4.7 billion in the same period). But this trading is strongly linked to the identity of the stock.
For stocks that have a large market capitalisation (market cap) like Infosys, there are always a large number of traders to buy and sell. Traders come with different trading impulses — speculative, liquidity-motivated or those that want to take out arbitrage — but their presence generates market liquidity for the shares of that stock. But there are fewer people who want to trade small market cap stocks. Instead, such stocks are traded in response to news or viral events, and mispricing is not easy to correct (Shah and Sharma, 2026). Their order book is often empty, i.e. liquidity is poor. Policy makers see small and medium enterprises as drivers of employment and growth, and exchanges have set up separate platforms for such stocks, but liquidity there remains stubbornly low (Aggarwal and Thomas, 2017).
Economic underdevelopment and low state capability could exacerbate this problem. For example, Shah and Thomas (2003) find that the large firms had 3X the liquidity of small firms on the NASDAQ in 2001, but that on the NSE, large firms had 34X the liquidity of small firms in the same year. With lower trading costs in India, trading firms should be more willing to allocate trader time to small stocks. Algorithmic trading is expected to reshape this problem in a positive direction (Aggarwal and Thomas, 2014). While a small traded product may not justify placing employees, a human controlling computer software may direct trading attention on a large number of small firms.
In this article, we use public data for equity market liquidity, to measure and analyse the evolution of cross-sectional variation in market liquidity in India.
Measuring liquidity
Measuring liquidity is not simple, because it varies across multiple dimensions — price, quantity, time. A good measure of liquidity is constructed from the limit order book, where hypothetical trades can be simulated and the price impact measured as a function of quantity and time. This was a key innovation that was used in the construction of Nifty. However, this measure requires continuous time snapshots of the limit order book which is not readily available. The poor man’s liquidity measure is the `turnover ratio’, which is the ratio of the latest one year’s traded value divided by today’s market cap.
For variation by size, we classify firms by market cap, in each year. Small firms are those at, or below the 10th percentile of market cap, and Large firms are above the 90th percentile. We calculate the market liquidity measures separately for the spot and derivatives, for both the aggregate market as well as for individual stocks.
We select five years across a 20 year span: 2005, 2010, 2015, 2020 and 2025. During this period, some events are likely to positively impact liquidity. At the start of this period, single stock futures and options (SSFnO) was thinly traded, but increased subsequently from 2010 onward; the pandemic in 2020 triggered a surge in retail investors trading using mobile phones.
Our analysis draws on two primary data sources. We use daily firm-level data from CMIE Prowess, covering all firms listed on both the NSE and BSE, for spot market data. A total of 6,494 firms in Prowess, traded on the spot market, at least in one of the five years selected for the analysis. Data for single stock derivatives is collected from archived NSE daily Bhavcopy data. For single stock futures, we use the traded value reported in the Bhavcopy, which equals the number of contracts traded x lot size x Bhavcopy price. For single stock options, we calculate traded value the same way, with the price taken as the strike price plus the option premium.
Our SSFnO sample only includes securities whose Bhavcopy ticker matches a firm in CMIE Prowess.1 Out of the 6,494 firms with trading on the spot market, 382 firms trade SSFnO in at least one of the selected five years. Of these, 138 firms stopped trading SSFnO in a later selected year, even though they continued to trade on the spot market. 21 of these 138 firms later started trading SSFnO again.
Table 1: Market cap characteristics of the samples (in nominal Rs. bln)
| No. of firms | Min | 25th | 50th | 75th | Max | |
|---|---|---|---|---|---|---|
| Panel A: all firms in the sample | ||||||
| 2005 | 2619 | 0.0007 | 0.05 | 0.18 | 1.01 | 1,103.45 |
| 2010 | 3106 | 0.0008 | 0.12 | 0.48 | 2.70 | 3,289.68 |
| 2015 | 3495 | 0.0032 | 0.14 | 0.60 | 4.18 | 4,829.48 |
| 2020 | 4202 | 0.0004 | 0.08 | 0.38 | 3.36 | 8,566.75 |
| 2025 | 5015 | 0.0002 | 0.41 | 1.97 | 15.41 | 18,659.96 |
| Panel B: firms with SSFnO trading | ||||||
| 2005 | 43 | 4.37 | 52.41 | 105.79 | 168.82 | 1,103.45 |
| 2010 | 213 | 3.64 | 24.69 | 54.61 | 173.00 | 3,289.68 |
| 2015 | 133 | 24.89 | 103.16 | 235.39 | 557.80 | 4,829.48 |
| 2020 | 186 | 6.82 | 92.36 | 228.12 | 546.02 | 8,566.75 |
| 2025 | 239 | 91.98 | 379.07 | 748.11 | 1,366.95 | 18,659.96 |
| Panel C: small and large firms by market cap | ||||||
| 2005 (Small ≤ Rs.0.02 bln; Large > Rs.4.86 bln) | ||||||
| Small | 144 | 0.0007 | 0.01 | 0.01 | 0.01 | 0.02 |
| Large | 290 | 4.86 | 7.46 | 12.54 | 32.64 | 1,103.45 |
| 2010 (Small ≤ Rs.0.04 bln; Large > Rs.15.58 bln) | ||||||
| Small | 206 | 0.0008 | 0.02 | 0.02 | 0.03 | 0.04 |
| Large | 332 | 15.65 | 26.18 | 45.12 | 124.48 | 3,289.68 |
| 2015 (Small ≤ Rs.0.03 bln; Large > Rs.22.02 bln) | ||||||
| Small | 183 | 0.0032 | 0.02 | 0.02 | 0.03 | 0.03 |
| Large | 397 | 22.14 | 34.52 | 63.59 | 171.39 | 4,829.48 |
| 2020 (Small ≤ Rs.0.03 bln; Large > Rs.30.77 bln) | ||||||
| Small | 372 | 0.0004 | 0.01 | 0.02 | 0.02 | 0.03 |
| Large | 432 | 31.02 | 52.29 | 109.43 | 238.84 | 8,566.75 |
| 2025 (Small ≤ Rs.0.12 bln; Large > Rs.106.31 bln) | ||||||
| Small | 499 | 0.0002 | 0.04 | 0.06 | 0.09 | 0.12 |
| Large | 502 | 107.08 | 171.91 | 311.60 | 780.48 | 18,659.96 |
Panel A in Table 1 shows that the full sample started with around 2500 firms, but this increased to more than 5000 in 2025. From 2010 to 2020, more than half the firms had market cap of Rs.0.5 billion, or more, but a quarter of the firms have market cap less than Rs.140 million.
Firms trading SSFnO (Panel B) are consistently larger. More than 50 percent have market cap more than Rs.200 billion throughout the sample, since 2015. But they are also fewer in number — typically less than 250 firms each year — suggesting that there has been limited growth in the number of large firms in the country.
Panel C describes small vs. large firms. In 2005, small firms were 1000 times smaller than large firms. This difference has steadily increased, with small firms being more than 5000 times smaller in 2020, and 2025. Large firm market cap grew faster than small firm market cap.
Our sample captures relative size in a year: small and large firms are the bottom and top market cap deciles of each year. One argument could be that the definition of what are small and large firms will be very different from the start to the end of a 20-year period. As a robustness check, we identify a sample of large vs. small firms by constant real size. This then refers to `small’ and `large’ firms of the same real size of firm in every year. For this, we first take the median market cap of the bottom and top deciles of the 2026 sample. We deflate these median values to the prices of each of 2005, 2010, 2015, 2020 and 2025. For a given year, small firms are those with market cap that fall within 0.95-1.05 times the real bottom decile market cap value for the year, while large firms are those that fall within 0.95-1.05 times the real top decile market cap value. This gives a smaller count of both large and small firms. There are between 25-51 small firms each year, with a median market cap Rs.0.02 billion in 2005 and Rs.0.07 billion in 2025. There are even fewer large firms (4-17 each year), with median market cap of Rs.79 billion in 2005, Rs.282 billion in 2025.
Findings
- How has aggregate market liquidity evolved over the last two decades?
Figure 1: Aggregate market turnover ratio (TR) for all firms in the sample, split into spot and SSFnO, selected years
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.


